N-(2-Oxo-2-((4-sulfamoylphenyl)amino)ethyl)-2-phenylacetamide

Catalog No. :
ACSNDK139
CAS No. :
795282-95-0
Molecular Formula :
C16H17N3O4S
Molecular Weight :
347.40

IUPAC Name:N-(2-oxo-2-((4-sulfamoylphenyl)amino)ethyl)-2-phenylacetamide

N-(2-Oxo-2-((4-sulfamoylphenyl)amino)ethyl)-2-phenylacetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25mg98%$483.00Login to see priceInquiryInquiry
50mg98%$821.00Login to see priceInquiryInquiry
100mg98%$1396.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(2-Oxo-2-((4-sulfamoylphenyl)amino)ethyl)-2-phenylacetamide
IUPAC NameN-(2-oxo-2-((4-sulfamoylphenyl)amino)ethyl)-2-phenylacetamide
Molecular FormulaC16H17N3O4S
Molecular Weight347.40
SMILESNS(=O)(C1=CC=C(C=C1)NC(CNC(CC2=CC=CC=C2)=O)=O)=O
InChI KeyBENISJFFZHKEMM-UHFFFAOYSA-N
SynonymBenzeneacetamide, N-[2-[[4-(aminosulfonyl)phenyl]amino]-2-oxoethyl]-;WAY-637940;N-(2-Oxo-2-((4-sulfamoylphenyl)amino)ethyl)-2-phenylacetamide
CAS No.795282-95-0
PubChem CID2444304

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACSNDK139 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSNDK139 route product structure diagram
    ACSNDK139795282-95-0
Inquiry

2. ACSNDK139 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYKIP713 route compound structure diagram
    ACYKIP7136101-31-1 In Stock
  2. Plus
  3. ACPELW961 route compound structure diagram
    ACPELW961500-98-1 In Stock
  4. Then
  5. ACSNDK139 route product structure diagram
    ACSNDK139795282-95-0
Inquiry

Comments (0)